The chemotherapy/radiation balance in advanced Hodgkin's lymphoma: Overweight which side?

Journal of Clinical Oncology

Volumn 23, Issue 36, 2005, Pages 9058-9062

  Carde, Patrice ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; JANUS KINASE INHIBITOR; LOMUSTINE; MELPHALAN; PREDNISOLONE; PREDNISONE; PROCARBAZINE; PROTEASOME; PROTEIN TYROSINE KINASE INHIBITOR; VINBLASTINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DRUG DOSE REDUCTION; EDITORIAL; HODGKIN DISEASE; HUMAN; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; CONTROLLED CLINICAL TRIAL; DECISION MAKING; NOTE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DECISION MAKING; HODGKIN DISEASE; HUMANS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 33644831408     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.4644     Document Type: Editorial

References (42)

1. Aleman BMP, Raemaekers JMM, Tirelli U, et al: Involved field radiotherapy in patients with advanced Hodgkin's lymphoma: An EORTC Lymphoma Group randomized controlled trial (#20884). N Engl J Med 348:2396-2406, 2003
2. Canellos GP, Anderson JR, Propert KI, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
3. Carde P, Cavalli F, Diehl V, et al: Treatment of advanced Hodgkin's disease: Is there a standard treatment? Hematol J 1:282-290, 2000
4. Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21:607-614, 2003
5. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
6. National Cancer Institute: EORTC protocol 20012/Intergroup trial: BEACOPP (4 cycles escalated + 4 cycles baseline) versus ABVD (8 cycles) in unfavorable (IPS 3+) stage III & IV Hodgkin Lymphoma. http://www.cancer .gov/clinicaltrials/EORTC-20012
7. Gobbi PG, Levis A, Chisesi T, et al: ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23:9198-9207, 2005
8. Johnson WM, Radford JA, Cullen MH, et al: Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial. J Clin Oncol 23:9208-9218, 2005
9. Horning SJ, Hoppe RT, Breslin S, et al: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's Disease: Mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002
10. Bonadonna G, Bonfante V, Viviani S, et al: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol 22:2835-2841, 2004
11. Gobbi PG, Pieresca C, Ghirardelli ML, et al: Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. Blood 91:2704-2712, 1998
12. Yahalom J: Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol 66:90-97, 2005
13. Canellos GP, Gollub J, Neuberg D, et al: Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol 14:268-272, 2003
14. Chisesi T, Federico M, Levis A, et al: ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: Results of a randomised trial. Ann Oncol 13:102-106, 2002 (suppl 1)
15. Martinelli G, Cocorocchio E, Peccatori F, et al: ChIVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: A retrospective analysis. Br J Haematol 125:584-589, 2004
16. Salvagno L, Soraru M, Sotti G, et al: Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease. Ann Oncol 6:173-179, 1995
17. Sieber M, Tesch H, Pfistner B, et al: Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: Final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol 15:276-282, 2004
18. Bartlett NL, Rosenberg SA, Hoppe RT, et al: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J Clin Oncol 13:1080-1088, 1995
19. Ferme C, Mounier N, Divine M: Current clinical trials for the treatment of adult advanced-stage Hodgkin's disease: GELA experiences-Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 13:96-97, 2002 (suppl 1)
20. Horning SJ, Williams J, Bartlett NL, et al: Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's Disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 18:972-980, 2000
21. Laskar S, Gupta T, Vimal S, et al: Consolidation radiation after complete remission in Hodgkin's dissase following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? J Clin Oncol 22:62-68, 2004
22. Hancock SL, Hoppe RT: Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 6:225-242, 1996
23. Longo DL: Radiation therapy in the treatment of Hodgkin's disease: Do you see what I see? J Natl Cancer Inst 95:928-929, 2003
24. Mauch P, Ng AK, Aleman B, et al: Report from the Rockefeller Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol 75:68-76, 2005
25. Loeffler M, Hasenclever D, Sextro M, et al: Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 16:818-829, 1998
26. Hasenclever D, Brosteanu O, Gerike T, et al: Modelling of chemotherapy: The effective dose approach. Ann Hematol 80:B89-B94, 2001 (suppl 3)
27. Carde P: Risks of infertility and early menopause from anticancer and immunosuppressive programs: Methods of fertility preservation and palliation. Am Soc Clin Oncol Ed Book, 2004, pp 400-417
28. Girinsky T, Pichenot C, Beaudre A, et al: Is intensity-modulated radiotherapy better than conventional radiation treatment and 3D conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease and is there a role for beam orientation optimization and virtual volumes? Int J Radiat Oncol Biol Phys 2005 (Sep 15 [Epub ahead of print])
29. Noordijk EM, Thomas J, Fermé C, et al: First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). J Clin Oncol 23:561, 2005 (suppl; abstr 6505)
30. Meyer RM, Gospodarowicz MK, Connors JM, et al: Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634-4642, 2005
31. Sieber M, Tesch H, Pfistner B, et al: Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: Final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol 20:476-484, 2002
32. Federico M, Bellei M, Brice P, et al: High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 21:2320-2325, 2003
33. Pfreundschuh MG, Ho A, Wolf M, et al: Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without ntuximab in young good-prognosis patients with aggressive lymphomas: Rituximab is an "equalizer" in the MinT (MABTHERA International Trial group) study. J Clin Oncol 23:567, 2005 (suppl; abstr 6529)
34. Brosteanu O, Hasenclever D, Loeffler M, et al: Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Ann Hematol 83:176-182, 2004
35. Taylor CR: Hodgkin's disease is a non-Hodgkin lymphoma. Hum Pathol 36:1-4, 2005
36. Engels EA, Goedert JJ: Human immunodeficiency virus/acquired immunodeficiency syndrome and cancer: Past, present, and future. J Natl Cancer Inst 97:407-409, 2005
37. Schnell R, Dietlein M, Staak JO, et al: Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 23:4669-4678, 2005
38. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
39. Henry-Amar M: Hodgkin's disease: Treatment sequelae and quality of life. Baillieres Clin Haematol 9:595-618, 1996
40. Carde P, M'kacher R, Bennaceur-Griscelli A, et al: Shortened telomeres in peripheral lymphocytes are associated to complex chromosome anomalies and to second cancers in Hodgkin Lymphoma patients. J Clin Oncol 23:563, 2005 (suppl; abstr 6512)
41. Carde P, Koscielny S, Franklin J, et al: Early response to chemotherapy: A surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol 13:86-91, 2002 (suppl 1)
42. Juweid ME, Cheson BD: Role of positron emission tomography in lymphoma. J Clin Oncol 23:4577-4580, 2005